Effects of viremia and CD4 recovery on gut “microbiome-immunity” axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy

Table 1 Features of the enrolled patients

	Age	Sex	ART regimen	Comorbidities	Timepoints (wk)	Viral load (copies/mL)	CD4+ cells/mm3	CD8+ cells/mm3	CD4/CD8 ratio
1	37	Male	3TC/ABC/DTG	No	T0	597463	110	420	0.3
					T24	< 20	520	832	0.6
2	38	Male	FTC/TDF/EVG/C	No	T0	4489	630	670	0.9
					T24	TND	831	740	1.1
3	34	Male	FTC/TDF/EVG/C	No	T0	165516	253	725	0.3
					T24	TND	504	363	1.4
4	39	Male	FTC/TDF/EVG/c	No	T0	859883	360	974	0.4
					T24	33	781	986	0.8
5	38	Male	3TC/ABC/DTG	No	T0	4860	1341	928	1.4
					T24	TND	1881	988	1.9
6	41	Male	FTC/TDF/RPV	Atrial fibrillation	T0	213	814	690	1.2
					T24	TND	845	519	1.6
7	25	Male	3TC/ABC/DTG	No	T0	23098	516	1149	0.4
					T24	< 20	942	1019	0.9
8	22	Male	FTC/TAF/EVG/c	No	T0	12188	654	1055	0.6
					T24	TND	668	733	0.9
9	48	Male	3TC/ABC/DTG	No	T0	175	833	1520	0.5
					T24	TND	941	1258	0.7
10	53	Male	3TC/ABC/DTG	Hypertension, HCV	T0	40545	863	1196	0.7
					T24	TND	612	515	1.2
11	40	Male	3TC/ABC/DTG	No	T0	859000	399	980	0.4
					T24	39	648	652	1
12	51	Male	FTC/TDF DTG	Diabetes	T0	4410	884	1066	0.8
					T24	< 20	1130	1261	0.9

ART: Antiretroviral therapy; 3TC: Lamivudine; ABC: Abacavir; DTG: Dolutegravir; FTC: Emtricitabine; TDF: Tenovir; EVG/c: Elvitegravir/cobi; RPV: Rilpivirine.